Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria
Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT...
Gespeichert in:
Veröffentlicht in: | World journal of clinical cases 2022-10, Vol.10 (29), p.10413-10427 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 10427 |
---|---|
container_issue | 29 |
container_start_page | 10413 |
container_title | World journal of clinical cases |
container_volume | 10 |
creator | Ince, Volkan Sahin, Tevfik Tolga Akbulut, Sami Yilmaz, Sezai |
description | Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians. |
doi_str_mv | 10.12998/wjcc.v10.i29.10413 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9602233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2730648875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-5e7cd1bf4a5899acd32f9a60032b04313818c0a0999769e21d031ce706b6fcb73</originalsourceid><addsrcrecordid>eNplkU1LxDAQhosouOj-Ai89euk6SfoVD4Is6goLXvQcpmnqZkmbmqQV_73dD0TxNDPMzDvD-0TRFYEFoZyXN59bKRfjVGrKFwRSwk6iGWVQJCXP4fRXfh7Nvd8CACGQkZzNonqtR-Xi4LDzvcEuYNC2ixvr4o3qMVipjBkMuliik7qzLd7GK-2DdVqiidVozbBfsc0_Fel0UE7jZXTWoPFqfowX0dvjw-tylaxfnp6X9-tEpmkZkkwVsiZVk2JWco6yZrThmAMwWkHKCCtJKQGBc17kXFFSAyNSFZBXeSOrgl1EdwfdfqhaVUvVTR8Z0TvdovsSFrX42-n0RrzbUUzWUMrYJHB9FHD2Y1A-iFb7nQPYKTt4QQsGeVqWRTaNssOodNZ7p5qfMwTEnovYcRETFzFxEXsu7BtDJYZg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2730648875</pqid></control><display><type>article</type><title>Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria</title><source>Baishideng "World Journal of" online journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ince, Volkan ; Sahin, Tevfik Tolga ; Akbulut, Sami ; Yilmaz, Sezai</creator><creatorcontrib>Ince, Volkan ; Sahin, Tevfik Tolga ; Akbulut, Sami ; Yilmaz, Sezai</creatorcontrib><description>Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians.</description><identifier>ISSN: 2307-8960</identifier><identifier>EISSN: 2307-8960</identifier><identifier>DOI: 10.12998/wjcc.v10.i29.10413</identifier><language>eng</language><publisher>Baishideng Publishing Group Inc</publisher><subject>Review</subject><ispartof>World journal of clinical cases, 2022-10, Vol.10 (29), p.10413-10427</ispartof><rights>The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-5e7cd1bf4a5899acd32f9a60032b04313818c0a0999769e21d031ce706b6fcb73</citedby><cites>FETCH-LOGICAL-c448t-5e7cd1bf4a5899acd32f9a60032b04313818c0a0999769e21d031ce706b6fcb73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602233/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602233/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Ince, Volkan</creatorcontrib><creatorcontrib>Sahin, Tevfik Tolga</creatorcontrib><creatorcontrib>Akbulut, Sami</creatorcontrib><creatorcontrib>Yilmaz, Sezai</creatorcontrib><title>Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria</title><title>World journal of clinical cases</title><description>Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians.</description><subject>Review</subject><issn>2307-8960</issn><issn>2307-8960</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNplkU1LxDAQhosouOj-Ai89euk6SfoVD4Is6goLXvQcpmnqZkmbmqQV_73dD0TxNDPMzDvD-0TRFYEFoZyXN59bKRfjVGrKFwRSwk6iGWVQJCXP4fRXfh7Nvd8CACGQkZzNonqtR-Xi4LDzvcEuYNC2ixvr4o3qMVipjBkMuliik7qzLd7GK-2DdVqiidVozbBfsc0_Fel0UE7jZXTWoPFqfowX0dvjw-tylaxfnp6X9-tEpmkZkkwVsiZVk2JWco6yZrThmAMwWkHKCCtJKQGBc17kXFFSAyNSFZBXeSOrgl1EdwfdfqhaVUvVTR8Z0TvdovsSFrX42-n0RrzbUUzWUMrYJHB9FHD2Y1A-iFb7nQPYKTt4QQsGeVqWRTaNssOodNZ7p5qfMwTEnovYcRETFzFxEXsu7BtDJYZg</recordid><startdate>20221016</startdate><enddate>20221016</enddate><creator>Ince, Volkan</creator><creator>Sahin, Tevfik Tolga</creator><creator>Akbulut, Sami</creator><creator>Yilmaz, Sezai</creator><general>Baishideng Publishing Group Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221016</creationdate><title>Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria</title><author>Ince, Volkan ; Sahin, Tevfik Tolga ; Akbulut, Sami ; Yilmaz, Sezai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-5e7cd1bf4a5899acd32f9a60032b04313818c0a0999769e21d031ce706b6fcb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Ince, Volkan</creatorcontrib><creatorcontrib>Sahin, Tevfik Tolga</creatorcontrib><creatorcontrib>Akbulut, Sami</creatorcontrib><creatorcontrib>Yilmaz, Sezai</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of clinical cases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ince, Volkan</au><au>Sahin, Tevfik Tolga</au><au>Akbulut, Sami</au><au>Yilmaz, Sezai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria</atitle><jtitle>World journal of clinical cases</jtitle><date>2022-10-16</date><risdate>2022</risdate><volume>10</volume><issue>29</issue><spage>10413</spage><epage>10427</epage><pages>10413-10427</pages><issn>2307-8960</issn><eissn>2307-8960</eissn><abstract>Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians.</abstract><pub>Baishideng Publishing Group Inc</pub><doi>10.12998/wjcc.v10.i29.10413</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2307-8960 |
ispartof | World journal of clinical cases, 2022-10, Vol.10 (29), p.10413-10427 |
issn | 2307-8960 2307-8960 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9602233 |
source | Baishideng "World Journal of" online journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Review |
title | Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T11%3A33%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20transplantation%20for%20hepatocellular%20carcinoma:%20Historical%20evolution%20of%20transplantation%20criteria&rft.jtitle=World%20journal%20of%20clinical%20cases&rft.au=Ince,%20Volkan&rft.date=2022-10-16&rft.volume=10&rft.issue=29&rft.spage=10413&rft.epage=10427&rft.pages=10413-10427&rft.issn=2307-8960&rft.eissn=2307-8960&rft_id=info:doi/10.12998/wjcc.v10.i29.10413&rft_dat=%3Cproquest_pubme%3E2730648875%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2730648875&rft_id=info:pmid/&rfr_iscdi=true |